One failed Glaxo CEO candidate on board, another to leave

LONDON (MarketWatch) -- GlaxoSmithKline
GSK, -0.48%GSK, +0.13%
said it was adding Chris Viehbacher, president of U.S. pharmaceuticals, to its board, while David Stoudt, president of pharmaceuticals, will leave the firm in February. Both were candidates for Glaxo's CEO post, which will be filled by Andrew Witty, who also will join the board. Eddie Gray, general manager of pharmaceuticals U.K., will succeed Witty as president of pharmaceuticals Europe.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information.
All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
Intraday data delayed at least 15 minutes or per exchange requirements.